Payment overview · 2025
General Payments
$336.19
16 reported records · 8 companies
Healthcare provider profile · identity verified
Kerry Keaffaber, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHIPSHEWANA, IN · NPI 1740226307
Verified facts
What the public records show
CMS Open Payments records show Kerry Keaffaber, MD received $336.19 in general payments during 2025 across 16 reported records.
Lundbeck LLC accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 455 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $113.69 | 33.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.42 | 15.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.98 | 12.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.37 | 10.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.13 | 10.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.42 | 7.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.52 | 6.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.66 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.34 | 15 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $113.69 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.42 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.42 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 455 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
148 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
455 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1370 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1183 | 80 |
| Gabapentin | Gabapentin | 1140 | 54 |
| Furosemide | Furosemide | 973 | 66 |
| Losartan Potassium | Losartan Potassium | 916 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 817 | 86 |
| Trazodone Hcl | Trazodone Hcl | 763 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 694 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 685 | 83 |
| Potassium Chloride | Potassium Chloride | 639 | 39 |
| Metformin Hcl | Metformin Hcl | 566 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 550 | 57 |
| Lisinopril | Lisinopril | 533 | 65 |
| Eliquis | Apixaban | 455 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 441 | 27 |
| Omeprazole | Omeprazole | 408 | 59 |
| Carvedilol | Carvedilol | 406 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 398 | 53 |
| Donepezil Hcl | Donepezil Hcl | 365 | 15 |
| Sertraline Hcl | Sertraline Hcl | 324 | 39 |
| Allopurinol | Allopurinol | 310 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 281 | 30 |
| Simvastatin | Simvastatin | 281 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 267 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 262 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 28 |
| Memantine Hcl | Memantine Hcl | 258 | 11 |
| Metformin Hcl Er | Metformin Hcl | 231 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 28 |
| Famotidine | Famotidine | 220 | 11 |
| Warfarin Sodium | Warfarin Sodium | 217 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 208 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 197 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 192 | suppressed |
| Bupropion Xl | Bupropion Hcl | 192 | 25 |
| Xarelto | Rivaroxaban | 180 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 174 | suppressed |
| Meloxicam | Meloxicam | 167 | 39 |
| Torsemide | Torsemide | 159 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 155 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 155 | 16 |
| Trulicity | Dulaglutide | 148 | 21 |
| Januvia | Sitagliptin Phosphate | 145 | suppressed |
| Jardiance | Empagliflozin | 141 | 11 |
| Midodrine Hcl | Midodrine Hcl | 139 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 12 |
| Glimepiride | Glimepiride | 131 | 14 |
| Propranolol Hcl | Propranolol Hcl | 128 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 41 |
| Divalproex Sodium | Divalproex Sodium | 119 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 114 | suppressed |
| Bumetanide | Bumetanide | 113 | suppressed |
| Mirtazapine | Mirtazapine | 103 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 86 | 17 |
| Alprazolam | Alprazolam | 84 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | suppressed |
| Entresto | Sacubitril/Valsartan | 81 | suppressed |
| Atenolol | Atenolol | 80 | suppressed |
| Prednisone | Prednisone | 80 | 26 |
| Spironolactone | Spironolactone | 79 | 11 |
| Pregabalin | Pregabalin | 78 | suppressed |
| Finasteride | Finasteride | 75 | 17 |
| Valsartan | Valsartan | 74 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 72 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 67 | 16 |
| Cephalexin | Cephalexin | 66 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | suppressed |
| Irbesartan | Irbesartan | 63 | suppressed |
| Ozempic | Semaglutide | 60 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 57 | 17 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 57 | suppressed |
| Nadolol | Nadolol | 57 | suppressed |
| Haloperidol | Haloperidol | 56 | suppressed |
| Novolog Flexpen | Insulin Aspart | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 17 |
| Risperidone | Risperidone | 54 | suppressed |
| Galantamine Er | Galantamine Hbr | 53 | suppressed |
| Glipizide | Glipizide | 53 | suppressed |
| Lorazepam | Lorazepam | 53 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 52 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 24 |
| Flecainide Acetate | Flecainide Acetate | 50 | suppressed |
| Lovastatin | Lovastatin | 50 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 41 |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Gemtesa | Vibegron | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Clozapine | Clozapine | 33 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 21 |
| Estradiol | Estradiol | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 31 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Fluocinonide | Fluocinonide | 27 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 15 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 11 |
| Nitroglycerin | Nitroglycerin | 17 | 15 |
| Temazepam | Temazepam | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Fluconazole | Fluconazole | 16 | 13 |
| Leflunomide | Leflunomide | 16 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 12 |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Metronidazole | Metronidazole | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $336.19 · 16 records | Lundbeck LLC | Cologuard Collection Kit, ELIQUIS, INGREZZA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, VRAYLAR, VYEPTI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error